Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is a somatostatin analogue. Its effects in the body are similar to those of the naturally occurring hormone, except that Sandostatin® LAR Depot remains active much longer than somatostatin.1
Octreotide is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Also, like somatostatin, Sandostatin® LAR Depot suppresses LH response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide.2 By doing so, it can significantly reduce severe diarrhea and flushing that are associated with excess quantities of these bioactive substances.3,4
Sandostatin® LAR Depot’s mechanism of action slows intestinal transport:
- Rapid gastrointestinal (GI) transit leads to accumulation of fluid in the colon and profuse volumes of watery stool5
- Sandostatin® (octreotide acetate) slows GI transit and increases fluid absorption by over 300%6
Highlights Of Important Safety Information
Bradycardia, arrhythmia, conduction abnormalities, and other EKG changes may occur. The relationship of these events to octreotide acetate is not established because many of these patients have underlying cardiac disease. Use with caution in at-risk patients.
Sandostatin® LAR Depot (octreotide acetate for injectable suspension) Mechanism of Action
See how Sandostatin® LAR Depot works to suppress the overproduction of certain peptides and amines associated with carcinoid syndrome.